Cargando...

Combining immunotherapies for the treatment of prostate cancer

Sipuleucel-T, a therapeutic dendritic-cell vaccine, was Food and Drug Administration-approved for prostate cancer in 2010. No new immunotherapies for prostate cancer have been approved since. However, novel agents and combination approaches offer great promise for improving outcomes for prostate can...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Urol Oncol
Autores principales: Redman, Jason M., Gulley, James L., Madan, Ravi A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6599516/
https://ncbi.nlm.nih.gov/pubmed/29146441
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2017.09.024
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!